AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26540079 — intervention group
Group type: COMPARATOR
Intervention: Control Group (not specified)
Number of subjects: 326
Study 25178112 — intervention group
Group type: COMPARATOR
Intervention: High-dose inhaled fluticasone propionate (FP)
Number of subjects: 40
Study 25178112 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 40
Study 25178112 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose inhaled fluticasone propionate (FP)
Number of subjects: 40
Study 22491567 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine‐gluconate (CHG) (4%) scrub
Number of subjects: 40
Study 22491567 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine‐gluconate (CHG) (4%) spray
Number of subjects: 40
Study 22491567 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone‐iodine (PI) (10%) scrub
Number of subjects: 40
Study 22491567 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone‐iodine (PI) (10%) spray
Number of subjects: 40
Study 22491567 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 40
Study 20629810 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan/HCTZ
Number of subjects: 468
Study 18313750 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback during practice interviews
Number of subjects: 0
Study 18313750 — intervention group
Group type: COMPARATOR
Intervention: Post-interview feedback
Number of subjects: 0
Study 18313750 — intervention group
Group type: COMPARATOR
Intervention: No feedback
Number of subjects: 0
Study 16326674 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75% plus lornoxicam 8 mg (Group RL)
Number of subjects: 80
Study 16326674 — intervention group
Group type: COMPARATOR
Intervention: Saline (Group S)
Number of subjects: 80
Study 12357143 — intervention group
Group type: EXPERIMENTAL
Intervention: PaCO(2) at 20, 30, 40, 50, or 60 mmHg maintained for 45 min
Number of subjects: 10
Study 12357143 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild intraoperative hypercapnia (increased PaCO(2))
Number of subjects: 10
Study 10224178 — intervention group
Group type: EXPERIMENTAL
Intervention: Literacy promoting intervention (bilingual children's book, bilingual handout, literacy-promoting guidance)
Number of subjects: 135
Study 10224178 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 135
Study 9101851 — intervention group
Group type: EXPERIMENTAL
Intervention: Transanal microsurgery (TEM) for T1-carcinomas
Number of subjects: 241
Study 9101851 — intervention group
Group type: EXPERIMENTAL
Intervention: Transanal microsurgery (TEM) for adenomas
Number of subjects: 241
Study 9101851 — intervention group
Group type: COMPARATOR
Intervention: Transanal microsurgery (TEM) and anterior resection (AR) for T1-carcinomas
Number of subjects: 241
Study 1806490 — intervention group
Group type: EXPERIMENTAL
Intervention: Biosynthetic human growth hormone (hGH) 0.03 mg/kg subcutaneously 3 times a week for 12 months (6-18 months experimental period)
Number of subjects: 45
Study 1806490 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control group)
Number of subjects: 45
Study 1806490 — intervention group
Group type: EXPERIMENTAL
Intervention: Biosynthetic human growth hormone (hGH)
Number of subjects: 45
Study 6613689 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg ascorbic acid daily for two weeks
Number of subjects: 10
Study 6613689 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg ascorbic acid daily
Number of subjects: 10
Study 31805862 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of Rifampicin (SDR) at double the regular dose (20 mg/kg) provided to eligible contacts aged two years and above in arms 2, 3, and 4.
Number of subjects: 0
Study 31805862 — intervention group
Group type: COMPARATOR
Intervention: No PEP provided (Arm 1 - comparator).
Number of subjects: 0
Study 28592299 — intervention group
Group type: EXPERIMENTAL
Intervention: Real biofield therapy
Number of subjects: 62
Study 28592299 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 62
Study 26466314 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary n-3 polyunsaturated fatty acids (PUFAs) intake, mean intake 2.0 ± 1.3 g/day
Number of subjects: 111
Study 26466314 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary alpha-linolenic acid (ALA) intake, mean intake 1.5 ± 1.0 g/day
Number of subjects: 111
Study 26466314 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratio of n-6/n-3 PUFAs, mean ratio 9.5 ± 6.7 g/day
Number of subjects: 111
Study 23549520 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone and valacyclovir plus physical therapy (n = 39)
Number of subjects: 87
Study 23549520 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological therapy only (n = 48)
Number of subjects: 87
Study 21165628 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arabinose (2 g) with sucrose (40 g)
Number of subjects: 21
Study 21165628 — intervention group
Group type: COMPARATOR
Intervention: Sucrose (40 g) without L-arabinose
Number of subjects: 21
Study 18836708 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 12
Study 18836708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 17722836 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and moxibustion
Number of subjects: 0
Study 17722836 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 15687760 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly health promotion program (16 weeks)
Number of subjects: 64
Study 15687760 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 64
Study 11719117 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (2 g)
Number of subjects: 116
Study 11719117 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 116
Study 9413958 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 13-cis-retinoic acid at 20 mg/day
Number of subjects: 12
Study 9413958 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 13-cis-retinoic acid at 40 mg every other day
Number of subjects: 12
Study 9413958 — intervention group
Group type: COMPARATOR
Intervention: Recombinant interferon alpha2a (rIFN-alpha2a) at 3 x 10(6) IU s.c. every other day
Number of subjects: 12
Study 8386921 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (ACE inhibitor)
Number of subjects: 30
Study 8386921 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (calcium antagonist)
Number of subjects: 30
Study 8386921 — intervention group
Group type: COMPARATOR
Intervention: Furosemide and Atenolol (loop diuretic and beta-blocker)
Number of subjects: 30
Study 8386921 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril and Diltiazem
Number of subjects: 30
Study 8386921 — intervention group
Group type: COMPARATOR
Intervention: Furosemide and Atenolol
Number of subjects: 30
Study 3318429 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 mg nabumetone once daily
Number of subjects: 100
Study 3318429 — intervention group
Group type: COMPARATOR
Intervention: 250 mg naproxen twice daily
Number of subjects: 100
Study 3318429 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabumetone (open-label treatment)
Number of subjects: 100
Study 28426624 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone (25 mg daily for 1 week, then up to 50 mg daily for 8 weeks)
Number of subjects: 15
Study 28426624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 27425658 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed Sequence (Random Interval 25 s schedule of reinforcement, correct feeder changed every 3 min, repeated four times)
Number of subjects: 6
Study 27425658 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable Sequence (Random Interval 25 s schedule of reinforcement, correct feeder changed in a randomized order)
Number of subjects: 6
Study 25911587 — intervention group
Group type: EXPERIMENTAL
Intervention: LightCycler® SeptiFast PCR test
Number of subjects: 78
Study 25911587 — intervention group
Group type: COMPARATOR
Intervention: Standard blood culture (BC) testing
Number of subjects: 78
Study 23524365 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage (10 minutes of massage of the trapezius muscle)
Number of subjects: 20
Study 23524365 — intervention group
Group type: EXPERIMENTAL
Intervention: Active exercise (10 minutes of shoulder shrugs with increasing elastic resistance)
Number of subjects: 20
Study 23524365 — intervention group
Group type: COMPARATOR
Intervention: Passive control (contralateral shoulder without treatment)
Number of subjects: 20
Study 21383004 — intervention group
Group type: EXPERIMENTAL
Intervention: Night-time ingestion of antihypertensives
Number of subjects: 0
Study 21383004 — intervention group
Group type: COMPARATOR
Intervention: Morning ingestion of antihypertensives
Number of subjects: 0
Study 19109560 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose platelet transfusions (150-<300 x 10(9) platelets/product)
Number of subjects: 119
Study 19109560 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose platelet transfusions (300-600 x 10(9) platelets/product)
Number of subjects: 119
Study 19109560 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose platelet transfusions
Number of subjects: 119
Study 19109560 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose platelet transfusions
Number of subjects: 119
Study 17364286 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate plus N‐acetyl cysteine
Number of subjects: 573
Study 17364286 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate alone
Number of subjects: 573
Study 15187171 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayley Infant Neurodevelopmental Screener (BINS) administered at 6 and 13 months
Number of subjects: 106
Study 15187171 — intervention group
Group type: COMPARATOR
Intervention: Bayley Scales of Infant Development, second edition (BSID‐II) administered at 24 months
Number of subjects: 106
Study 15187171 — intervention group
Group type: EXPERIMENTAL
Intervention: BINS with cut score set below 90
Number of subjects: 106
Study 11159994 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble toxoids (n = 5)
Number of subjects: 30
Study 11159994 — intervention group
Group type: EXPERIMENTAL
Intervention: Toxoids adsorbed to alum (n = 5)
Number of subjects: 30
Study 11159994 — intervention group
Group type: COMPARATOR
Intervention: Toxoids adsorbed to alum
Number of subjects: 30
Study 11159994 — intervention group
Group type: EXPERIMENTAL
Intervention: All formulations
Number of subjects: 30
Study 10211048 — intervention group
Group type: EXPERIMENTAL
Intervention: HF and red-pepper (10 g) meal
Number of subjects: 13
Study 10211048 — intervention group
Group type: EXPERIMENTAL
Intervention: HC and red-pepper meal
Number of subjects: 13
Study 10211048 — intervention group
Group type: COMPARATOR
Intervention: HF meal
Number of subjects: 13
Study 10211048 — intervention group
Group type: COMPARATOR
Intervention: HC meal
Number of subjects: 13
Study 8788579 — intervention group
Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 32
Study 8788579 — intervention group
Group type: EXPERIMENTAL
Intervention: Transaxillary first rib resection
Number of subjects: 32
Study 8788579 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraclavicular decompression (reoperation)
Number of subjects: 32
Study 2224198 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviourally‐based self‐help manual
Number of subjects: 107
Study 2224198 — intervention group
Group type: COMPARATOR
Intervention: General advice and information booklet (Control)
Number of subjects: 107
Study 2224198 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help manual with opportunity to make progress reports to a telephone answering service
Number of subjects: 107
Study 2224198 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help manual with opportunity to make telephoned progress reports to an interviewer
Number of subjects: 107
Study 74324 — intervention group
Group type: EXPERIMENTAL
Intervention: High ability to concentrate
Number of subjects: 21
Study 74324 — intervention group
Group type: EXPERIMENTAL
Intervention: Average ability to concentrate
Number of subjects: 21
Study 74324 — intervention group
Group type: COMPARATOR
Intervention: Low ability to concentrate
Number of subjects: 21
Study 26808357 — intervention group
Group type: EXPERIMENTAL
Intervention: Ctrough model for digoxin
Number of subjects: 452
Study 26808357 — intervention group
Group type: EXPERIMENTAL
Intervention: Cmax model for digoxin
Number of subjects: 452
Study 28390503 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive media‐based, computer‐delivered depression treatment program (imbPST)
Number of subjects: 45
Study 28390503 — intervention group
Group type: COMPARATOR
Intervention: No Treatment Control (NTC)
Number of subjects: 45
Study 26297323 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental treatment (automated texting smoking intervention)
Number of subjects: 200
Study 26297323 — intervention group
Group type: COMPARATOR
Intervention: Attention control (not specified in detail)
Number of subjects: 200
Study 26678710 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol (1g every 4 hours for 72 hours)
Number of subjects: 41
Study 26678710 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sodium chloride (saline) (0.9% saline every 4 hours for 72 hours)
Number of subjects: 41
Study 24633277 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour antibiotic regimen (Ampicillin/Cloxacillin and Metronidazole)
Number of subjects: 200
Study 24633277 — intervention group
Group type: COMPARATOR
Intervention: 7-day antibiotic regimen (Ampicillin/Cloxacillin and Metronidazole)
Number of subjects: 200
Study 24633277 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost of antibiotics for short term prophylaxis
Number of subjects: 200
Study 24633277 — intervention group
Group type: COMPARATOR
Intervention: Cost of antibiotics for long term prophylaxis
Number of subjects: 200
Study 21920501 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy for pathological gambling plus a standard drug therapy for schizophrenia
Number of subjects: 44
Study 21920501 — intervention group
Group type: COMPARATOR
Intervention: Standard drug therapy for schizophrenia
Number of subjects: 44
Study 18333946 — intervention group
Group type: EXPERIMENTAL
Intervention: pH-balanced gel (pH 3.8-4.2) with regular size, non-applicator tampons
Number of subjects: 98
Study 18333946 — intervention group
Group type: EXPERIMENTAL
Intervention: Existing lubricating gel (pH 5.1) with regular size, non-applicator tampons
Number of subjects: 98
Study 18333946 — intervention group
Group type: COMPARATOR
Intervention: Non-lubricated tampons
Number of subjects: 98
Study 17157123 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50-100 mg/d)
Number of subjects: 40
Study 17157123 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5-10 mg/d)
Number of subjects: 40
Study 17157123 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 40
Study 14748202 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 8 mg once daily
Number of subjects: 12218
Study 14748202 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12218
Study 10925341 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent
Number of subjects: 400
Study 10925341 — intervention group
Group type: COMPARATOR
Intervention: Angioplasty
Number of subjects: 400
Study 9528197 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (500 mg thrice daily for 14 days) + omeprazole (twice daily for 20 days and once for one month) + metronidazole (500 mg twice daily for 10 days)
Number of subjects: 123
Study 9528197 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin (twice daily for 14 days) + omeprazole (twice daily for 20 days and once for one month) + metronidazole (500 mg twice daily for 10 days)
Number of subjects: 123
Study 9528197 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg once daily for 6 days) + omeprazole (twice daily for 20 days and once for one month) + metronidazole (500 mg twice daily for 10 days)
Number of subjects: 123
Study 7930131 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Temperature (OT)
Number of subjects: 65
Study 7930131 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary Temperature (AT)
Number of subjects: 65
Study 7930131 — intervention group
Group type: COMPARATOR
Intervention: Tympanic Membrane Temperature (TMT)
Number of subjects: 65
Study 7930131 — intervention group
Group type: COMPARATOR
Intervention: Rectal Temperature (RT)
Number of subjects: 65
Study 3219156 — intervention group
Group type: EXPERIMENTAL
Intervention: KW-3049 (benidipine hydrochloride) 2 x 8 mg
Number of subjects: 0
Study 3219156 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine 2 x 10 mg
Number of subjects: 0
Study 3219156 — intervention group
Group type: EXPERIMENTAL
Intervention: KW-3049 (benidipine hydrochloride)
Number of subjects: 0
Study 3219156 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 0
Study 3219156 — intervention group
Group type: EXPERIMENTAL
Intervention: KW-3049 (benidipine hydrochloride) and Nifedipine
Number of subjects: 0
Study 31959549 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral resection (TUR)
Number of subjects: 126
Study 31959549 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral coagulation (TUC)
Number of subjects: 126
Study 31959549 — intervention group
Group type: COMPARATOR
Intervention: Both TUR and TUC
Number of subjects: 126
Study 29325517 — intervention group
Group type: EXPERIMENTAL
Intervention: The Daily Mile (15 minutes of running or walking integrated into the school day for 12 months)
Number of subjects: 40
Study 29325517 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (control)
Number of subjects: 40
Study 29325517 — intervention group
Group type: EXPERIMENTAL
Intervention: The Daily Mile
Number of subjects: 40
Study 26879683 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA plus climen
Number of subjects: 124
Study 26879683 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA plus climen (high-FSH subgroup)
Number of subjects: 124
Study 26879683 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA plus climen (low-FSH subgroup)
Number of subjects: 124
Study 26879683 — intervention group
Group type: COMPARATOR
Intervention: DHEA
Number of subjects: 124
Study 25782347 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry Eye Disease (DED) group
Number of subjects: 45
Study 25782347 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study 23038989 — intervention group
Group type: EXPERIMENTAL
Intervention: BZA 20 mg/CE 0.45 mg
Number of subjects: 1061
Study 23038989 — intervention group
Group type: EXPERIMENTAL
Intervention: BZA 20 mg/CE 0.625 mg
Number of subjects: 1061
Study 23038989 — intervention group
Group type: COMPARATOR
Intervention: CE 0.45 mg/MPA 1.5 mg
Number of subjects: 1061
Study 23038989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1061
Study 21436597 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan add-on treatment
Number of subjects: 3031
Study 21436597 — intervention group
Group type: COMPARATOR
Intervention: Non-ARB treatment (Control)
Number of subjects: 3031
Study 21436597 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan treatment
Number of subjects: 3031
Study 19159566 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-resistant regimen (3RFT AM Ofx Pto PAS-INH/5RFT Ofx Pto PAS-INH)
Number of subjects: 154
Study 19159566 — intervention group
Group type: COMPARATOR
Intervention: Retreatment regimen (3 H3R3Z3E3S3/5 H3R3E3)
Number of subjects: 154
Study 19159566 — intervention group
Group type: EXPERIMENTAL
Intervention: MDR-TB patients on drug-resistant regimen
Number of subjects: 154
Study 19159566 — intervention group
Group type: COMPARATOR
Intervention: MDR-TB patients on retreatment regimen
Number of subjects: 154
Study 19159566 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-resistant regimen
Number of subjects: 154
Study 19159566 — intervention group
Group type: COMPARATOR
Intervention: Retreatment regimen
Number of subjects: 154
Study 16512974 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided cannulation (Group 2)
Number of subjects: 30
Study 16512974 — intervention group
Group type: COMPARATOR
Intervention: Traditional palpation method (Group 1)
Number of subjects: 30
Study 16512974 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsiflexion effect on artery size
Number of subjects: 30
Study 14634601 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 32
Study 14634601 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 32
Study 14634601 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 32
Study 14634601 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam/Flumazenil
Number of subjects: 32
Study 10759030 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl-cysteine
Number of subjects: 69
Study 10759030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 8837903 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide 400 mg daily
Number of subjects: 694
Study 8837903 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 694
Study 7908356 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate zidovudine (250 mg four times daily)
Number of subjects: 1749
Study 7908356 — intervention group
Group type: COMPARATOR
Intervention: Deferred zidovudine (placebo)
Number of subjects: 1749
Study 3067330 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (De‐Nol) 300 mg four times daily with ASA
Number of subjects: 10
Study 3067330 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (ASA) 2.5 g plus placebo
Number of subjects: 10
Study 29404725 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab 8 mg + MTX
Number of subjects: 9753
Study 29404725 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab 8 mg
Number of subjects: 9753
Study 29404725 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab 200 mg
Number of subjects: 9753
Study 29404725 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab 200 mg + MTX
Number of subjects: 9753
Study 29404725 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirukumab 100 mg
Number of subjects: 9753
Study 29404725 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab 4 mg + MTX
Number of subjects: 9753